한글목차

속효성 인슐린 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 115억 4,000만 달러에서 2026년에는 121억 4,000만 달러에 이르고, CAGR 5.3%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 높은 당뇨병 유병률, 인슐린 치료의 보급 확대, 병원 기반 당뇨병 관리, 인슐린 접근성 프로그램 확대, 당뇨병 진단율 향상 등을 꼽을 수 있습니다.

속효성 인슐린 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 148억 7,000만 달러에 이르고, CAGR은 5.2%를 나타낼 전망입니다. 예측 기간 동안의 성장에는 2형 당뇨병 유병률 증가, 인슐린 의존성 증가, 재택 당뇨병 치료 확대, 인슐린 투여 기술 발전, 속효성 인슐린에 대한 수요 증가 등이 주요 요인으로 작용할 것으로 보입니다. 주요 동향으로는 식후 혈당 조절에 대한 수요 증가, 속효성 인슐린 유사체 사용 확대, 프리필드 인슐린 펜의 보급, 집중 인슐린 요법 요법의 확대, 엄격한 혈당 관리에 대한 집중 강화 등을 들 수 있습니다.

1형 당뇨병의 유병률 증가는 향후 몇 년 동안 단시간 지속형 인슐린 시장의 성장을 견인할 것으로 예측됩니다. 1형 당뇨병은 자가면역질환으로 면역체계가 인슐린을 생산하는 세포를 공격하기 때문에 평생 인슐린 치료가 필수적입니다. 1형 당뇨병 환자 증가는 유전적 소인, 환경적 요인, 자가면역질환 증가가 복합적으로 작용한 결과로 보고 있습니다. 속효성 인슐린은 혈당을 빠르게 조절하고 체내 자연 인슐린 반응을 충실하게 재현하여 1형 당뇨병 관리에 도움을 줍니다. 예를 들어, 2023년 12월 호주의 당뇨병 인식 개선 단체인 'Diabetes Australia'가 발표한 자료에 따르면, 2022년 기준 약 13만 4,000명의 호주인이 1형 당뇨병을 앓고 있으며, 2023년에는 13만 5,423명으로 증가 증가할 것으로 예측됩니다. 이처럼 1형 당뇨병 유병률 증가는 단시간 지속형 인슐린 시장의 성장에 기여하고 있습니다.

속효성 인슐린 분야의 주요 기업들은 혈당 조절을 개선하고 당뇨병 환자의 유연한 대체를 위해 교체 가능한 속효성 인슐린 생물학적 제제 등 혁신적인 솔루션 개발에 주력하고 있습니다. 교체형 속효성 인슐린 생물학적 제제는 식후 혈당을 빠르게 낮추는 생물 유래 인슐린으로, 규제 당국으로부터 동등한 인슐린 제품과의 대체가 승인되어 새로운 처방이 필요하지 않으며, 일관성 있고 적응력 있는 당뇨병 관리를 지원합니다. 예를 들어, 2025년 7월 인도와 미국에 본사를 둔 미국 바이오시밀러 기업 바이오콘 바이오로직스는 미국 최초의 교체형 속효성 인슐린 아스파트 제제 '카스티(인슐린 아스파트-xjhz)'에 대한 FDA 승인을 받았습니다. 키르스티는 노보로직(인슐린 아스파트)의 바이오시밀러로 안전성, 유효성, 순도, 효능에 있어 유의미한 차이가 없음을 임상 데이터 및 분석 데이터를 통해 확인하였습니다. 성인 및 소아 당뇨병 환자의 혈당 조절을 개선하기 위해 100단위/mL 제형으로 피하 투여용 1회용 프리필드 펜과 피하 및 정맥 투여용 다회용 바이알로 제공되며, 성인 및 소아 당뇨병 환자의 혈당 조절을 개선하기 위해 개발되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Short-acting insulin is a form of insulin used to manage blood glucose levels during or following meals. It starts acting within 30 minutes to 1 hour, reaches its peak effect at about 2-3 hours, and remains effective for 4-6 hours. Short-acting insulin is essential for controlling blood sugar by helping glucose enter the body's cells, where it is utilized for energy, especially after food intake.

The primary formulation types of short-acting insulin include regular insulin and rapid-acting insulin. Regular insulin is a fast-acting insulin used to manage blood glucose levels in individuals with diabetes and is usually administered prior to meals. These formulations are offered in multiple dosage forms, such as vials, pre-filled pens, and cartridges, and can be delivered via subcutaneous or intravenous routes. It is prescribed for patients with both type 1 and type 2 diabetes and is distributed through various channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

Tariffs have influenced the short-acting insulin market by increasing the cost of importing active pharmaceutical ingredients, recombinant insulin, cartridges, and pre-filled pen components used in diabetes treatment. Vials, cartridges, and pen-based insulin products are most affected, particularly in North America and Asia-Pacific where global insulin supply chains are heavily utilized. Hospital pharmacies and retail pharmacies face higher procurement and distribution costs. However, tariffs are encouraging domestic insulin manufacturing and local fill-and-finish operations, supporting long-term supply stability and pricing control.

The short-acting insulin market research report is one of a series of new reports from The Business Research Company that provides short-acting insulin market statistics, including short-acting insulin industry global market size, regional shares, competitors with a short-acting insulin market share, detailed short-acting insulin market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting insulin industry. This short-acting insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The short-acting insulin market size has grown strongly in recent years. It will grow from $11.54 billion in 2025 to $12.14 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to high prevalence of diabetes, widespread insulin therapy adoption, hospital-based diabetes management, expansion of insulin access programs, improved diabetes diagnosis rates.

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising type 2 diabetes incidence, increasing insulin dependence, growth in home-based diabetes care, expansion of insulin delivery technologies, rising demand for fast-acting insulin. Major trends in the forecast period include rising demand for post-meal blood glucose control, increasing use of rapid-acting insulin analogues, growing adoption of pre-filled insulin pens, expansion of intensive insulin therapy regimens, increased focus on tight glycemic management.

The growing prevalence of type 1 diabetes is anticipated to drive the expansion of the short-acting insulin market in the coming years. Type 1 diabetes is an autoimmune disorder in which the immune system attacks insulin-producing cells, making lifelong insulin treatment essential. The increase in Type 1 diabetes cases is attributed to a combination of genetic predisposition, environmental influences, and a rise in autoimmune conditions. Short-acting insulin supports the management of type 1 diabetes by enabling rapid regulation of blood glucose levels and closely replicating the body's natural insulin response. For example, in December 2023, Diabetes Australia, an Australia-based organization focused on diabetes awareness, reported that around 134,000 Australians were living with Type 1 diabetes in 2022, a number that rose to 135,423 in 2023. As a result, the rising prevalence of type 1 diabetes is contributing to the growth of the short-acting insulin market.

Major companies operating in the short-acting insulin space are focusing on developing innovative solutions such as interchangeable rapid-acting insulin biologics to improve glycemic control and allow flexible substitution for people with diabetes. An interchangeable rapid-acting insulin biologic is a biologically derived insulin that acts quickly to reduce post-meal blood glucose levels and is approved by regulators to be substituted for an equivalent insulin product without requiring a new prescription, supporting consistent and adaptable diabetes management. For instance, in July 2025, Biocon Biologics, a U.S.-based biosimilars company headquartered in India and the United States, received FDA approval for Kirsty (insulin aspart-xjhz), the first and only interchangeable rapid-acting insulin aspart in the U.S. Kirsty is a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no meaningful differences in safety, efficacy, purity, or potency, and is available as a 100 units/mL formulation in both a single-use prefilled pen for subcutaneous administration and a multidose vial for subcutaneous and intravenous use, aimed at improving glycemic control in adults and children with diabetes mellitus.

In December 2024, Lupin Limited, an India-based pharmaceutical firm, acquired the Humulin portfolio in India from Eli Lilly & Company for an undisclosed sum. Through this acquisition, Lupin seeks to reinforce its presence in the Indian insulin space by broadening its product offerings with the inclusion of Huminsulin from Eli Lilly and Company. Eli Lilly and Company is a US-based pharmaceutical organization focused on insulin therapies, including short-acting insulin products.

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the short-acting insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short-Acting Insulin Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses short-acting insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for short-acting insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The short-acting insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Formulation: Regular Insulin; Rapid-Acting Insulin
• 2) By Dosage Form: Vials; Pre-filled Pens; Cartridges
• 3) By Route Of Administration: Subcutaneous; Intravenous
• 4) By Patient Type: Type 1 Diabetes; Type 2 Diabetes
• 5) By Distribution Channel: Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Regular Insulin: Human Regular Insulin; Animal-Derived Regular Insulin; Other Regular Insulin
• 2) By Rapid-Acting Insulin: Insulin Lispro; Insulin Aspart; Insulin Glulisine
• Companies Mentioned: Sanofi S.A.; Eli Lilly and Company; Novo Nordisk A/S; Biocon Limited; Lupin Limited; Wockhardt Ltd.; Julphar (Gulf Pharmaceutical Industries); Geropharm LLC; Bioton S.A.; Gan & Lee Pharmaceuticals Co. Ltd.; Lannett Company Inc.; MannKind Corporation; ADOCIA S.A.S.; Baxter International Inc.; Tonghua Dongbao Pharmaceutical Co. Ltd.; United Laboratories International Holdings Ltd.; Bharat Biotech International Ltd.; Shanghai Fosun Pharmaceutical Group Co. Ltd.; Dongbao Enterprise Group Co. Ltd.; Aspen Pharmacare Holdings Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Short-Acting Insulin Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Short-Acting Insulin Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Short-Acting Insulin Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Short-Acting Insulin Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Rising Demand For Post-Meal Blood Glucose Control
  • 4.2.2 Increasing Use Of Rapid-Acting Insulin Analogues
  • 4.2.3 Growing Adoption Of Pre-Filled Insulin Pens
  • 4.2.4 Expansion Of Intensive Insulin Therapy Regimens
  • 4.2.5 Increased Focus On Tight Glycemic Management

5. Short-Acting Insulin Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diabetes Clinics
• 5.3 Retail Pharmacies
• 5.4 Homecare Patients
• 5.5 Specialty Pharmacies

6. Short-Acting Insulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Short-Acting Insulin Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Short-Acting Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Short-Acting Insulin Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Short-Acting Insulin Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Short-Acting Insulin Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Short-Acting Insulin Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Short-Acting Insulin Market Segmentation

• 9.1. Global Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Regular Insulin, Rapid-Acting Insulin
• 9.2. Global Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vials, Pre-filled Pens, Cartridges
• 9.3. Global Short-Acting Insulin Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Subcutaneous, Intravenous
• 9.4. Global Short-Acting Insulin Market, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Type 1 Diabetes, Type 2 Diabetes
• 9.5. Global Short-Acting Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmacies, Hospital Pharmacies, Online Pharmacies
• 9.6. Global Short-Acting Insulin Market, Sub-Segmentation Of Regular Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin
• 9.7. Global Short-Acting Insulin Market, Sub-Segmentation Of Rapid-Acting Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Insulin Lispro, Insulin Aspart, Insulin Glulisine

10. Short-Acting Insulin Market Regional And Country Analysis

• 10.1. Global Short-Acting Insulin Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Short-Acting Insulin Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Short-Acting Insulin Market

• 11.1. Asia-Pacific Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Short-Acting Insulin Market

• 12.1. China Short-Acting Insulin Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Short-Acting Insulin Market

• 13.1. India Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Short-Acting Insulin Market

• 14.1. Japan Short-Acting Insulin Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Short-Acting Insulin Market

• 15.1. Australia Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Short-Acting Insulin Market

• 16.1. Indonesia Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Short-Acting Insulin Market

• 17.1. South Korea Short-Acting Insulin Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Short-Acting Insulin Market

• 18.1. Taiwan Short-Acting Insulin Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Short-Acting Insulin Market

• 19.1. South East Asia Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Short-Acting Insulin Market

• 20.1. Western Europe Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Short-Acting Insulin Market

• 21.1. UK Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Short-Acting Insulin Market

• 22.1. Germany Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Short-Acting Insulin Market

• 23.1. France Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Short-Acting Insulin Market

• 24.1. Italy Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Short-Acting Insulin Market

• 25.1. Spain Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Short-Acting Insulin Market

• 26.1. Eastern Europe Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Short-Acting Insulin Market

• 27.1. Russia Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Short-Acting Insulin Market

• 28.1. North America Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Short-Acting Insulin Market

• 29.1. USA Short-Acting Insulin Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Short-Acting Insulin Market

• 30.1. Canada Short-Acting Insulin Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Short-Acting Insulin Market

• 31.1. South America Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Short-Acting Insulin Market

• 32.1. Brazil Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Short-Acting Insulin Market

• 33.1. Middle East Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Short-Acting Insulin Market

• 34.1. Africa Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Short-Acting Insulin Market, Segmentation By Formulation, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Short-Acting Insulin Market Regulatory and Investment Landscape

36. Short-Acting Insulin Market Competitive Landscape And Company Profiles

• 36.1. Short-Acting Insulin Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Short-Acting Insulin Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Short-Acting Insulin Market Company Profiles
  • 36.3.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis

37. Short-Acting Insulin Market Other Major And Innovative Companies

• Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

38. Global Short-Acting Insulin Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Short-Acting Insulin Market

40. Short-Acting Insulin Market High Potential Countries, Segments and Strategies

• 40.1 Short-Acting Insulin Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Short-Acting Insulin Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Short-Acting Insulin Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer